Workflow
Profound Medical to Participate in Lake Street’s 9th Annual Best Ideas Growth Conference

Core Insights - Profound Medical Corp. is a commercial-stage medical device company focused on customizable, incision-free therapies for ablation of diseased tissue [3] Company Overview - Profound Medical Corp. is developing and marketing innovative medical technologies, including TULSA-PRO and Sonalleve, aimed at treating various medical conditions [3][4][5] TULSA-PRO Technology - TULSA-PRO combines real-time MRI, AI-enhanced planning, and robotically-driven ultrasound for precise treatment of prostate diseases, including cancer and benign prostatic hyperplasia [4] - The TULSA procedure is incision-free, radiation-free, and performed in a single session, with a treatment temperature of 55-57°C, ensuring minimal recovery time for patients [4] - TULSA-PRO has received CE marking, Health Canada approval, and 510(k) clearance from the FDA [4] Sonalleve Technology - Sonalleve is a therapeutic platform approved for treating uterine fibroids and palliative pain from bone metastases, with CE marking and FDA approval under a Humanitarian Device Exemption [5] - The technology is also approved by the China National Medical Products Administration for non-invasive treatment of uterine fibroids [5] - Profound is exploring additional treatment markets for Sonalleve, including non-invasive ablation of abdominal cancers [5] Upcoming Event - Management will participate in the Lake Street Capital Markets "BIG9" Conference on September 11, 2025, in New York City, with one-on-one investor meetings scheduled [1][2]